Table 3.

Nerve conduction study in patients with Type 2 diabetes stratified by ascending quartiles of glycemic variability (HbA SD).

	1st (n = 56)	2nd (n = 55)	3rd (n = 57)	4th (n = 55)	P-value for trend
MEDIAN NERVE, MOTOR
DML	4.2 ± 0.8	4.8 ± 1.2	4.3 ± 1.1	4.7 ± 1.3	0.02*
CMAP	8.6 ± 2.8	7.8 ± 2.3	8.2 ± 2.4	7.8 ± 2.8	0.25
MNCV	53.2 ± 4.8	50.9 ± 4.8	51.3 ± 4.1	49.0 ± 4.9	<0.0001**
ULNAR NERVE, MOTOR
DML	2.9 ± 0.4	3.0 ± 0.5	3.1 ± 0.8	3.2 ± 0.7	0.04*
CMAP	9.3 ± 2.6	8.6 ± 2.4	8.1 ± 2.8	7.1 ± 3.3	0.001*
MNCV	52.3 ± 6.9	49.1 ± 7.5	49.6 ± 7.1	48.0 ± 7.4	0.02*
PERONEAL NERVE
DML	4.1 ± 0.9	4.3 ± 1.0	4.3 ± 0.8	4.4 ± 1.1	0.7
CMAP	4.1 ± 2.5	3.2 ± 2.5	3.3 ± 2.2	2.8 ± 2.3	0.04*
MNCV	43.6 ± 5.5	41.5 ± 5.8	42.0 ± 5.4	40.2 ± 5.2	0.02*
TIBIAL NERVE
DML	4.3 ± 0.9	4.3 ± 0.9	4.4 ± 1.2	4.4 ± 0.8	0.9
CMAP	10.6 ± 5.4	8.7 ± 4.6	8.1 ± 4.5	6.7 ± 4.9	0.001*
MNCV	43.3 ± 5.0	41.5 ± 4.9	40.8 ± 4.8	39.4 ± 4.9	0.001*
MEDIAN NERVE, SENSORY
Latency	3.2 ± 1.3	3.5 ± 0.9	3.1 ± 0.7	3.4 ± 0.9	0.24
SNAP	29.4 ± 17.4	20.7 ± 14.4	23.1 ± 14.1	16.7 ± 14.6	<0.0001**
SNCV	46.5 ± 9.6	42.7 ± 9.9	46.2 ± 8.4	43.3 ± 10.8	0.09
ULNAR NERVE, SENSORY
Latency	2.3 ± 0.4	2.4 ± 0.3	2.5 ± 0.4	2.4 ± 0.5	0.3
SNAP	27.0 ± 16.7	19.3 ± 13.1	16.7 ± 13.9	12.4 ± 12.1	<0.0001**
SNCV	50.9 ± 9.7	61.0 ± 43.1	48.5 ± 6.7	49.5 ± 7.7	0.3
SURAL NERVE
Latency	2.9 ± 0.5	2.9 ± 0.6	3.1 ± 0.4	2.9 ± 0.9	0.24
SNAP	9.4 ± 6.1	8.2 ± 6.6	5.3 ± 4.9	4.6 ± 3.6	<0.0001**
SNCV	49.4 ± 6.7	47.2 ± 6.2	45.8 ± 6.5	46.2 ± 6.7	0.04*
Composite score of low extremities	4.8 ± 4.2	5.9 ± 4.4	6.3 ± 4.4	7.4 ± 4.8	0.026*

Data are presented as means ± standard deviations or n (%). n, number of cases; DML, distal motor latency; CMAP, compound muscles action potential; MNCV, motor nerve conduction velocity; SNAP, sensory nerve action potential; SNCV, sensory nerve conduction velocity.

^*p < 0.05,

^**p < 0.0001.

Bold values indicates statistical significance.